Hutchison China MediTech: Sovleplenib Phase 3 Study Meets Primary Endpoint
| Show full article |
|
This functionality is available for registred users only
|
-
Full nameHutchison China MediTech Limited
-
Registration countryCayman Islands
-
IndustryPharmaceutical Preparation and Biotechnology
-
М/S&P/F
*** /*** /***









